

Update for the Quarter Ending 30 June 2019

Brisbane, Australia, 29 July 2019 – ResApp Health Limited (ASX:RAP), a leading digital health company developing smartphone applications for the diagnosis and management of respiratory disease, is pleased to provide an update on the company's activities during the fourth quarter of the financial year, ending June 30, 2019.

"During the final quarter of the financial year we have expanded our commercial opportunity by receiving positive results from our adult pivotal clinical study and have progressed both our US and European regulatory submissions," said Tony Keating, CEO and Managing Director of ResApp. "We were pleased to see the first peer-reviewed publication from the Breathe Easy paediatric clinical study published in Respiratory Research. The press release from the publishers generated significant media interest in our technology – including national television coverage in Australia and print media in US, Europe and China. With our first two regulatory submissions (in Europe and the United States) progressing, complementary hardware solutions under development, and our in-home sleep apnoea study nearing completion, we are excited about the commercial opportunities in both the near and long-term."

Recent Highlights and Outlook

- **Progressing regulatory submissions in Europe and the US.** In April, ResApp submitted an application to the US Food and Drug Administration (FDA) for De Novo classification of ResAppDx-US. ResApp submitted a CE Mark Technical File for European approval of ResAppDx-EU in late December 2018. Both submissions are progressing through the review phases. The CE Mark process has taken longer than initially anticipated however the company has recently received advice from BSI that the process is now close to completion.
- **Positive results from Australian adult pivotal study.** In April, ResApp announced that it had received positive top-line results from its Australian double-blind, prospective clinical study in adults. ResApp's smartphone-based algorithms were found to accurately diagnose acute respiratory disease – achieving greater than 86% positive and negative percent agreement for lower respiratory tract disease and pneumonia compared with clinical diagnosis. The study also demonstrated that ResApp's algorithms accurately identified acute exacerbations in patients with a history of chronic obstructive pulmonary disease (COPD) or asthma and were able to accurately screen for COPD in a broad population. ResApp plans to use this data to support forthcoming CE and TGA submissions.
- **Formed Industry Advisory Board.** In June, ResApp announced that it has appointed Naomi Fried, PhD and Joseph C. Kvedar, MD to its newly established Industry Advisory Board. The Industry Advisory Board will provide ResApp with strategic counsel on the commercialisation of its diagnostic and management platform for respiratory disease. Dr Fried and Dr Kvedar are recognised leaders in digital health and bring a vast amount of experience from within the US

ResApp Health Limited ABN 51 094 468 318

Headquarters: Level 8, 127 Creek St, Brisbane QLD 4000 Australia

Registered Office: Level 24, 44 St Georges Tce, Perth WA 6000 Australia

T +61 8 6211 5099 E info@resapphealth.com.au W www.resapphealth.com.au



healthcare system. Dr Kvedar has been recently elected as the next president of the American Telemedicine Association.

- **Started development of complementary hardware devices.** In May, ResApp announced that it had engaged a UK-based medical device consultancy to develop customised hardware and wearable devices capable of running ResApp’s machine learning algorithms. Design of the two devices, a ruggedised handheld and a small, unobtrusive wearable monitor, has begun with functional prototypes expected later this calendar year and CE Mark approval targeted in 2020.
- **Results from Australian paediatric study published in peer-reviewed journal.** A publication titled, “A prospective multicentre study testing the diagnostic accuracy of an automated cough sound centred analytic system for the identification of common respiratory disorders in children” was published in the peer-reviewed medical journal *Respiratory Research* in June. The publication summarises results from the Australian Breathe Easy pivotal paediatric clinical study. Results from ResApp’s US-based SMARTCOUGH-C-2 paediatric clinical study were also presented at the American Thoracic Society 2019 International Conference in May. The ATS International Conference is the leading US respiratory conference and is attended by nearly 14,000 pulmonary, critical care, and sleep professionals.
- **Strong balance sheet to advance ResApp through commercialisation.** The Company held cash of \$5.5 million as of June 30, 2019 and is well-funded to execute its clinical and commercialisation strategy. In June, ResApp received \$1.785 million from its R&D tax incentive claim for the financial year ending 30 June 2018. A significant proportion of ResApp’s R&D spend for the financial year ending 30 June 2019 will also be eligible for the R&D tax incentive.

###

About ResApp Health Limited

ResApp Health Limited (ASX: RAP) is a leading digital health company developing smartphone applications for the diagnosis and management of respiratory disease. ResApp’s machine learning algorithms use sound to diagnose and measure the severity of respiratory conditions without the need for additional hardware. Clinical studies at leading hospitals in Australia and the United States have demonstrated accurate diagnosis of lower respiratory tract disease, upper respiratory tract infections, asthma/reactive airway disease, pneumonia, bronchiolitis, croup, chronic obstructive pulmonary disease and obstructive sleep apnoea. Potential customers of ResApp’s products include healthcare providers in telehealth, emergency department, urgent care and primary care settings as well as humanitarian organisations in the developing world. For more information, please visit www.resapphealth.com.au.

Contacts

Dr Tony Keating
CEO and Managing Director
+61 430 180 659
tony@resapphealth.com.au

Mr Brian Leedman
Vice President, Corporate Affairs
+61 412 281 780
brian@resapphealth.com.au

ResApp Health Limited ABN 51 094 468 318

Headquarters: Level 8, 127 Creek St, Brisbane QLD 4000 Australia

Registered Office: Level 24, 44 St Georges Tce, Perth WA 6000 Australia

T +61 8 6211 5099 **E** info@resapphealth.com.au **W** www.resapphealth.com.au

Appendix 4C

Quarterly report for entities subject to Listing Rule 4.7B

Introduced 31/03/00 Amended 30/09/01, 24/10/05, 17/12/10, 01/09/16

Name of entity

ResApp Health Limited

ABN

51 094 468 318

Quarter ended ("current quarter")

30 June 2019

Consolidated statement of cash flows	Current quarter \$A'000	Year to date (12 months) \$A'000
1. Cash flows from operating activities		
1.1 Receipts from customers	-	48
1.2 Payments for		
(a) research and development	(728)	(3,352)
(b) product manufacturing and operating costs	-	-
(c) advertising and marketing (see note 4)	(2)	(3)
(d) leased assets	-	-
(e) staff costs	(655)	(2,177)
(f) administration and corporate costs	(257)	(1,270)
1.3 Dividends received (see note 3)	-	-
1.4 Interest received	74	81
1.5 Interest and other costs of finance paid	-	-
1.6 Income taxes paid	-	-
1.7 Government grants and tax incentives	1,822	1,822
1.8 Other – R&D rebate	-	-
1.9 Net cash from / (used in) operating activities	254	(4,851)
2. Cash flows from investing activities		
2.1 Payments to acquire:		
(a) property, plant and equipment	(11)	(36)
(b) businesses (see item 10)	-	-
(c) investments	-	-

Consolidated statement of cash flows	Current quarter \$A'000	Year to date (12 months) \$A'000
(d) intellectual property	-	-
(e) other non-current assets	-	-
2.2 Proceeds from disposal of:		
(a) property, plant and equipment	-	-
(b) businesses (see item 10)	-	-
(c) investments	-	-
(d) intellectual property	-	-
(e) other non-current assets	-	-
2.3 Cash flows from loans to other entities	-	-
2.4 Dividends received (see note 3)	-	-
2.5 Other (provide details if material)	-	-
2.6 Net cash from / (used in) investing activities	(11)	(36)

3. Cash flows from financing activities		
3.1 Proceeds from issues of shares	-	7,500
3.2 Proceeds from issue of convertible notes	-	-
3.3 Proceeds from exercise of share options	-	-
3.4 Transaction costs related to issues of shares, convertible notes or options	-	(495)
3.5 Proceeds from borrowings	-	-
3.6 Repayment of borrowings	-	-
3.7 Transaction costs related to loans and borrowings	-	-
3.8 Dividends paid	-	-
3.9 Other (provide details if material)	-	-
3.10 Net cash from / (used in) financing activities	-	7,005

4. Net increase / (decrease) in cash and cash equivalents for the period		
4.1 Cash and cash equivalents at beginning of quarter/year to date	5,273	3,398
4.2 Net cash from / (used in) operating activities (item 1.9 above)	254	(4,851)
4.3 Net cash from / (used in) investing activities (item 2.6 above)	(11)	(36)
4.4 Net cash from / (used in) financing activities (item 3.10 above)	-	7,005

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (12 months) \$A'000
4.5	Effect of movement in exchange rates on cash held	-	-
4.6	Cash and cash equivalents at end of quarter	5,516	5,516

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter \$A'000	Previous quarter \$A'000
5.1	Bank balances	5,516	5,273
5.2	Call deposits	-	-
5.3	Bank overdrafts	-	-
5.4	Other (provide details)	-	-
5.5	Cash and cash equivalents at end of quarter (should equal item 4.6 above)	5,516	5,273

6. Payments to directors of the entity and their associates

- 6.1 Aggregate amount of payments to these parties included in item 1.2
- 6.2 Aggregate amount of cash flow from loans to these parties included in item 2.3
- 6.3 Include below any explanation necessary to understand the transactions included in items 6.1 and 6.2

Current quarter \$A'000
(127)

1. Director fees, salary and super; and
2. Consultancy fees.

7. Payments to related entities of the entity and their associates

- 7.1 Aggregate amount of payments to these parties included in item 1.2
- 7.2 Aggregate amount of cash flow from loans to these parties included in item 2.3
- 7.3 Include below any explanation necessary to understand the transactions included in items 7.1 and 7.2

Current quarter \$A'000

8. Financing facilities available <i>Add notes as necessary for an understanding of the position</i>	Total facility amount at quarter end \$A'000	Amount drawn at quarter end \$A'000
8.1 Loan facilities	-	-
8.2 Credit standby arrangements	-	-
8.3 Other (please specify)	-	-
8.4 Include below a description of each facility above, including the lender, interest rate and whether it is secured or unsecured. If any additional facilities have been entered into or are proposed to be entered into after quarter end, include details of those facilities as well.		

--

9. Estimated cash outflows for next quarter	\$A'000
9.1 Research and development	(924)
9.2 Product manufacturing and operating costs	-
9.3 Advertising and marketing	-
9.4 Leased assets	-
9.5 Staff costs	(678)
9.6 Administration and corporate costs	(238)
9.7 Other (provide details if material)	(10)
9.8 Total estimated cash outflows	(1,850)


10. Acquisitions and disposals of business entities (items 2.1(b) and 2.2(b) above)	Acquisitions	Disposals
10.1 Name of entity	-	-
10.2 Place of incorporation or registration	-	-
10.3 Consideration for acquisition or disposal	-	-
10.4 Total net assets	-	-
10.5 Nature of business	-	-

Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

Sign here:

.....
(Director)



Date: 29 July 2019

Print name: Tony Keating

Notes

1. The quarterly report provides a basis for informing the market how the entity's activities have been financed for the past quarter and the effect on its cash position. An entity that wishes to disclose additional information is encouraged to do so, in a note or notes included in or attached to this report.
2. If this quarterly report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.